BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21685412)

  • 1. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary.
    Estívariz CF; Molnár Z; Venczel L; Kapusinszky B; Zingeser JA; Lipskaya GY; Kew OM; Berencsi G; Csohán A
    Am J Epidemiol; 2011 Aug; 174(3):316-25. PubMed ID: 21685412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary.
    Kapusinszky B; Molnár Z; Szomor KN; Berencsi G
    FEMS Immunol Med Microbiol; 2010 Mar; 58(2):211-7. PubMed ID: 19863665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine.
    Kohler KA; Banerjee K; Gary Hlady W; Andrus JK; Sutter RW
    Bull World Health Organ; 2002; 80(3):210-6. PubMed ID: 11984607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91.
    Andrus JK; Strebel PM; de Quadros CA; Olivé JM
    Bull World Health Organ; 1995; 73(1):33-40. PubMed ID: 7704923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-associated paralytic poliomyelitis and other diseases with acute flaccid paralysis syndrome in Belarus.
    Samoilovich EO; Feldman EV; Yermalovich MA; Protas II; Titov LP
    Cent Eur J Public Health; 2003 Dec; 11(4):213-8. PubMed ID: 14768785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000.
    Hao L; Toyokawa S; Kobayashi Y
    Jpn J Infect Dis; 2008 Mar; 61(2):100-3. PubMed ID: 18362395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine--a risk factor for vaccine-associated paralytic poliomyelitis.
    Strebel PM; Ion-Nedelcu N; Baughman AL; Sutter RW; Cochi SL
    N Engl J Med; 1995 Feb; 332(8):500-6. PubMed ID: 7830731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of clincal poliomyelitis in Shandong Province from 1993-1996].
    Lei J; Li L; Xu A
    Zhonghua Liu Xing Bing Xue Za Zhi; 1998 Dec; 19(6):327-9. PubMed ID: 10921114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
    Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
    Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-associated paralytic poliomyelitis in the Russian Federation in 1998-2014.
    Ivanova OE; Eremeeva TP; Morozova NS; Shakaryan AK; Korotkova EA; Kozlovskaya LI; Baykova OY; Krasota AY; Gmyl AP
    Int J Infect Dis; 2018 Nov; 76():64-69. PubMed ID: 30201507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine policy changes and epidemiology of poliomyelitis in the United States.
    Alexander LN; Seward JF; Santibanez TA; Pallansch MA; Kew OM; Prevots DR; Strebel PM; Cono J; Wharton M; Orenstein WA; Sutter RW
    JAMA; 2004 Oct; 292(14):1696-701. PubMed ID: 15479934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imported vaccine-associated paralytic poliomyelitis--United States, 2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Feb; 55(4):97-9. PubMed ID: 16456525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Paralytic poliomyelitis in Russian Federation in 1998-2005].
    Ivanova OE; Eremeeva TP; Leshchinskaia EV; Korotkova EA; Iakovenko ML; Cherniavskaia OP; Cherkasova EA; Dragunskaia EM; Dekonenko EP; Martynenko IN; Krasnoproshina LI; Sorokina MP
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (5):37-44. PubMed ID: 18038545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
    Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
    Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paralytic poliomyelitis--United States, 1980-1994.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Jan; 46(4):79-83. PubMed ID: 9048844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poliovirus vaccine options.
    Zimmerman RK; Spann SJ
    Am Fam Physician; 1999 Jan; 59(1):113-8, 125-6. PubMed ID: 9917578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
    Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.